Matches in SemOpenAlex for { <https://semopenalex.org/work/W79388712> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W79388712 endingPage "9" @default.
- W79388712 startingPage "S13" @default.
- W79388712 abstract "This article presents critical aspects of the pivotal phase III study that led to approval of interferon beta-1a (Avonex) as treatment for relapsing-remitting multiple sclerosis (MS). An update on data from the pivotal study or other open studies, further demonstrating the practical clinical impact of Avonex, are also presented. The purpose of the pivotal study was to determine whether Avonex could slow the progressive irreversible neurological disability of relapsing-MS. 301 patients were randomised into a double-blind placebo-controlled, multicentric trial of Avonex. Avonex 6.0 MUI (30 micrograms) was administered by intramuscular injection weekly. The primary outcome variable was time to sustained physical disability at 6 months progression of at least 1.0 point on the EDSS. Avonex produced a significant delay in time to sustained EDSS progression (p = 0.02). The Kaplan-Meier estimate of the proportion of patients progressing by the end of 104 weeks was 34.9 p. 100 in the placebo group and 21.9 p. 100 in the Avonex treated group, representing a 37 p. 100 reduction in the risk of accumulating disability. Further analysis showed that the clinical efficacy related to disability did not depend on the definition of disability progression. Significantly fewer Avonex recipients progressed to EDSS milestones of 4.0 or 6.0. The exacerbation frequency was decreased by 32 p. 100 in the Avonex group. Patients treated with Avonex had also a significantly lower number and volume of gadolinium-enhanced lesions on MRI. There was no major adverse events related to treatment. Injection site reactions were rare and no reports of skin necrosis have been recorded. There was no significant and clinically relevant biological disturbances due to Avonex." @default.
- W79388712 created "2016-06-24" @default.
- W79388712 creator A5025462803 @default.
- W79388712 date "1999-01-01" @default.
- W79388712 modified "2023-09-25" @default.
- W79388712 title "[Interferon beta-1a (Avonex TM): clinical and MRI impacts]." @default.
- W79388712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10367320" @default.
- W79388712 hasPublicationYear "1999" @default.
- W79388712 type Work @default.
- W79388712 sameAs 79388712 @default.
- W79388712 citedByCount "0" @default.
- W79388712 crossrefType "journal-article" @default.
- W79388712 hasAuthorship W79388712A5025462803 @default.
- W79388712 hasConcept C126322002 @default.
- W79388712 hasConcept C142724271 @default.
- W79388712 hasConcept C197934379 @default.
- W79388712 hasConcept C203014093 @default.
- W79388712 hasConcept C204787440 @default.
- W79388712 hasConcept C27081682 @default.
- W79388712 hasConcept C2777014857 @default.
- W79388712 hasConcept C2780640218 @default.
- W79388712 hasConcept C2780892749 @default.
- W79388712 hasConcept C2908698914 @default.
- W79388712 hasConcept C2994247566 @default.
- W79388712 hasConcept C535046627 @default.
- W79388712 hasConcept C71924100 @default.
- W79388712 hasConceptScore W79388712C126322002 @default.
- W79388712 hasConceptScore W79388712C142724271 @default.
- W79388712 hasConceptScore W79388712C197934379 @default.
- W79388712 hasConceptScore W79388712C203014093 @default.
- W79388712 hasConceptScore W79388712C204787440 @default.
- W79388712 hasConceptScore W79388712C27081682 @default.
- W79388712 hasConceptScore W79388712C2777014857 @default.
- W79388712 hasConceptScore W79388712C2780640218 @default.
- W79388712 hasConceptScore W79388712C2780892749 @default.
- W79388712 hasConceptScore W79388712C2908698914 @default.
- W79388712 hasConceptScore W79388712C2994247566 @default.
- W79388712 hasConceptScore W79388712C535046627 @default.
- W79388712 hasConceptScore W79388712C71924100 @default.
- W79388712 hasLocation W793887121 @default.
- W79388712 hasOpenAccess W79388712 @default.
- W79388712 hasPrimaryLocation W793887121 @default.
- W79388712 hasRelatedWork W1974000699 @default.
- W79388712 hasRelatedWork W1986008120 @default.
- W79388712 hasRelatedWork W2012270273 @default.
- W79388712 hasRelatedWork W2054710763 @default.
- W79388712 hasRelatedWork W2112246282 @default.
- W79388712 hasRelatedWork W2113358607 @default.
- W79388712 hasRelatedWork W2408776304 @default.
- W79388712 hasRelatedWork W2461983894 @default.
- W79388712 hasRelatedWork W4205462144 @default.
- W79388712 hasRelatedWork W4210548604 @default.
- W79388712 hasVolume "155 Suppl 2" @default.
- W79388712 isParatext "false" @default.
- W79388712 isRetracted "false" @default.
- W79388712 magId "79388712" @default.
- W79388712 workType "article" @default.